How everyone on Medicare could end up paying for the pricey new Alzheimer's drug
1 min read
fairly easy
The controversial new drug for Alzheimer's disease, Aduhelm, is priced at $56,000 a year for treatment -- but Alzheimer's patients won't be the only ones shouldering the cost.

All of Medicare's roughly 60 million enrollees will likely see their premiums rise to cover the new medication, experts say -- and the burden will also fall to federal and state governments and, therefore, to taxpayers.

Here's how it's expected to work: Because Aduhelm will be administered in physicians' offices, it…
Tami Luhby, CNN
Read full article